​

Funding Round

Series A - Mirador Therapeutics

Series A - Mirador Therapeutics

Investment Firm

Overview

Mirador Therapeutics envisions precision medicine for immune-mediated inflammatory and fibrotic diseases.

Announced Date

Mar 21, 2024

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

ARCH Venture Partners

ARCH Venture Partners

ARCH Venture Partners is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.

Participant Investors

15

Investor Name
Participant InvestorTCG Crossover
Participant InvestorARCH Venture Partners
Participant InvestorPoint72 Ventures
Participant InvestorFidelity
Participant InvestorFarallon Capital Management

Round Details and Background

Mirador Therapeutics raised $400000000 on 2024-03-21 in Series A

Mirador Therapeutics envisions precision medicine for immune-mediated inflammatory and fibrotic diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 21, 2024
Series A - Mirador Therapeutics
17-400.0M
Mar 19, 2024
Debt Financing - Mirador Therapeutics
-undefined
Dec 14, 2023
Venture Round - Mirador Therapeutics
-80.0M

Recent Activity

There is no recent news or activity for this profile.